Datum Källa Rubrik Typ Alternativ
2023-01-10 Promore Pharma BioStock: Promore Pharmas vd om förhoppningarna för 2023 Pressreleaser Visa Stäng
2023-01-10 Promore Pharma BioStock: Promore Pharma's CEO on hopes for 2023 Pressreleaser Visa Stäng
2022-12-08 Västra Hamnen Market Focus Västra Hamnen Market Focus: Promore Pharma: Inväntar resultat Analyser Visa Stäng
2022-11-29 Promore Pharma Interim report January - September 2022 Analyser Ladda ner | Visa Stäng
Analyser | 29 Nov 2022 | Promore Pharma

Interim report January – September 2022

July to September

  • Net sales amounted to MSEK 0 (0)
  • Net loss was MSEK -5.3 (-6.1), corresponding to earnings per share of SEK -0.09 (-0.11)
  • Cash flow after financing activities amounted to MSEK -6.1 (+39.1)
  • Cash amounted to MSEK 23.5 (52.1), compared to MSEK 45.3 on 31 December 2021

January to September

  • Net sales amounted to MSEK 0 (0)
  • Net loss was MSEK -19.9 (-21.1), corresponding to earnings per share of SEK -0.33 (-0.49)
  • Cash flow after financing activities amounted to MSEK -21.8 (-27.9)

Significant events during January – September

  • In January 2022, warrants corresponding to a dilution of 0.2% of the number of outstanding shares were deregistered.
  • In February 2022, the first trial person was enrolled in PHSU05 (ensereptide).
  • The recruitment target for the study was achieved according to plan in March.
  • At the AGM in May, Marianne Dicander Alexandersson was elected new chairman of the board. Also, Candice Jung was elected new member of the board.
  • In September 2022, the last clinic visit in PHSU05 occurred (ensereptide).
  • In August 2022, the company received a granted patent in the European Union for the use of the candidate drug ropo-camptide (LL-37) for the treatment of chronic wounds.

Events after the reporting period

  • In November 2022, it was announced that results from PHSU05 are expected in April 2023, where the lack of special-ized staff and equipment is the reason for the slight delay

” The third quarter of the year has been characterized by continued progress within our two clinical development programs”

Jonas Ekblom, President and CEO of Promore Pharma

2022-11-29 Promore Pharma Delårsrapport januari – september 2022 Analyser Ladda ner | Visa Stäng
2022-11-24 Promore Pharma Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2022 Analyser Ladda ner | Visa Stäng
2022-11-24 Promore Pharma Inbjudan till presentation av Promore Pharmas delårsrapport för Q3 2022 Analyser Ladda ner | Visa Stäng
2022-11-23 Promore Pharma Nomination Committee Appointed for the Annual General Meeting 2023 in Promore Pharma Analyser Ladda ner | Visa Stäng
2022-11-23 Promore Pharma Valberedning utsedd inför årsstämma 2023 i Promore Pharma Analyser Ladda ner | Visa Stäng
2022-11-15 Analysguiden Analysguiden: ANALYS Promore Pharma: Resultat från fas 2 mot ärrbildning i april 2023 Analyser Ladda ner | Visa Stäng
2022-11-01 Promore Pharma Promore Pharma uppdaterar om sin kliniska Fas II-studie med ensereptide Analyser Ladda ner | Visa Stäng
2022-11-01 Promore Pharma Promore Pharma provides an update on the Phase II clinical trial with ensereptide Analyser Ladda ner | Visa Stäng
2022-09-21 Promore Pharma BioStock: Promore Pharma's leg ulcer treatment to reduce patient suffering Pressreleaser Visa Stäng
2022-09-21 Promore Pharma BioStock: Promore Pharmas bensårsbehandling ska minska patientens lidande Pressreleaser Visa Stäng
2022-09-05 Promore Pharma BioStock: Promore Pharma advancing according to plan Pressreleaser Visa Stäng
2022-09-05 Promore Pharma BioStock: Promore Pharma avancerar enligt plan Pressreleaser Visa Stäng
2022-09-01 Västra Hamnen Market Focus Västra Hamnen Market Focus: Promore Pharma: Utvecklingsarbetet fortlöper Analyser Visa Stäng
2022-08-30 Promore Pharma Promore Pharma Interim report January – June 2022 Analyser Ladda ner | Visa Stäng
2022-08-30 Promore Pharma Promore Pharma Delårsrapport januari – juni 2022 Analyser Ladda ner | Visa Stäng
2022-08-23 Promore Pharma Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Second Quarter 2022 Analyser Ladda ner | Visa Stäng
2022-08-23 Promore Pharma Inbjudan till telefonkonferens om Promore Pharmas rapport för det andra kvartalet 2022 Analyser Ladda ner | Visa Stäng
2022-08-15 Promore Pharma BioStock: Promore Pharma stärker patentskyddet Pressreleaser Visa Stäng
2022-08-15 Promore Pharma BioStock: Promore Pharma strengthens IP-protection Pressreleaser Visa Stäng
2022-08-10 Promore Pharma Promore Pharma granted EU patent regarding treatment of chronic wounds Analyser Ladda ner | Visa Stäng
2022-08-10 Promore Pharma Promore Pharma beviljas patent i Europa avseende behandling av kroniska sår Analyser Ladda ner | Visa Stäng
2022-06-17 Promore Pharma BioStock: Sista klinikbesöket genomfört i Promore Pharmas ensereptide-studie Pressreleaser Visa Stäng
2022-06-17 Promore Pharma BioStock: Last clinic visit completed in Promore Pharma's ensereptide study Pressreleaser Visa Stäng
2022-06-14 Analysguiden Analysguiden: ANALYS Promore Pharma: Rekryteringsmål uppnått i fas 2 mot ärrbildning Analyser Ladda ner | Visa Stäng
2022-06-13 Promore Pharma The last clinic visit conducted in Promore Pharma's phase II study of ensereptide Analyser Ladda ner | Visa Stäng
2022-06-13 Promore Pharma Sista klinikbesöket genomfört i Promore Pharmas fas II-studie av ensereptide Analyser Ladda ner | Visa Stäng
2022-05-25 Promore Pharma BioStock: Promore Pharma's Q1 characterised by study progress Pressreleaser Visa Stäng
2022-05-25 Promore Pharma BioStock: Promore Pharmas Q1 präglat av studieavancemang Pressreleaser Visa Stäng
2022-05-18 Västra Hamnen Market Focus Västra Hamnen Market Focus: Promore Pharma: Ärrstudie fullrekryterad Analyser Visa Stäng
2022-05-17 Promore Pharma Report from the Annual General Meeting of Promore Pharma AB held on 17 May 2022 Analyser Ladda ner | Visa Stäng
2022-05-17 Promore Pharma Kommuniké från Promore Pharma AB:s årsstämma den 17 maj 2022 Analyser Ladda ner | Visa Stäng
2022-05-17 Promore Pharma Promore Pharma -- delårsrapport januari-mars 2022 Analyser Ladda ner | Visa Stäng
2022-05-17 Promore Pharma Promore Pharma -- interim report January-March 2022 Analyser Ladda ner | Visa Stäng
2022-05-16 Promore Pharma BioStock: Promore Pharma vill påskynda läkning av venösa bensår Pressreleaser Visa Stäng
2022-05-16 Promore Pharma BioStock: Promore Pharma aims to accelerate healing of venous leg ulcers Pressreleaser Visa Stäng
2022-05-13 Promore Pharma Invitation to Conference Call regarding Promore Pharma’s Interim Report for the First Quarter 2022 Analyser Ladda ner | Visa Stäng
2022-05-13 Promore Pharma Inbjudan till telefonkonferens om Promore Pharmas rapport för det första kvartalet 2022 Analyser Ladda ner | Visa Stäng
2022-04-26 Promore Pharma Promore Pharmas årsredovisning för 2021 samt stämmohandlingar publicerade Analyser Ladda ner | Visa Stäng
2022-04-26 Promore Pharma Promore Pharma’s Annual Report 2021 and AGM related Documents Published Analyser Ladda ner | Visa Stäng
2022-04-12 Promore Pharma KALLELSE TILL ÅRSSTÄMMA I PROMORE PHARMA AB (PUBL) Analyser Ladda ner | Visa Stäng
2022-04-12 Promore Pharma NOTICE OF ANNUAL GENERAL MEETING PROMORE PHARMA AB (PUBL) Analyser Ladda ner | Visa Stäng
2022-04-07 Promore Pharma BioStock: Promore Pharmas fas II-studie pågår planenligt Pressreleaser Visa Stäng
2022-04-07 Promore Pharma BioStock: Promore Pharma's phase II study running according to plan Pressreleaser Visa Stäng

Kommande händelser

28 Feb 2023 | Bokslutskommuniké 2022
23 May 2023 | Årsstämma 2022